Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 5.01% | |
| Drug Manufacturers - General | 33.53% | 9.03% | |
| Medical Devices | 12.72% | 5.15% | |
| Healthcare Plans | 12.62% | -7.63% | |
| Biotechnology | 11.69% | 0.05% | |
| Diagnostics & Research | 10.84% | -0.40% | |
| Medical Instruments & Supplies | 7.89% | 25.18% | |
| Medical Care Facilities | 2.91% | 12.94% | |
| Drug Manufacturers - Specialty & Generic | 2.84% | -0.53% | |
| Medical Distribution | 2.50% | 17.09% | |
| Health Information Services | 2.34% | 20.80% | |
| Pharmaceutical Retailers | 0.12% | -65.58% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 826.71 | 999.43 | 11.36% | | | | Buy | |
| 549.62 | 625.10 | 7.73% | | | | Buy | |
| 149.31 | 175.98 | 5.49% | | | | Buy | |
| 176.19 | 208.90 | 4.76% | | | | Buy | |
| 103.09 | 133.43 | 3.99% | | | | Buy | |
| 529.36 | 657.43 | 3.09% | | | | Buy | |
| 115.60 | 130.24 | 3.06% | | | | Buy | |
| 550.41 | 539.24 | 3.00% | | | | Buy | |
| 230.12 | 288.34 | 2.54% | | | | Buy | |
| 385.02 | 396.33 | 2.24% | | | | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 144.28 | 39.535B | 0.09% | | |
| 266.95 | 20.562B | 0.10% | | |
| 99.14 | 7.257B | 0.35% | | |
| 141.30 | 6.968B | 0.45% | | |
| 60.17 | 4.768B | 0.40% | |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 212.19 | 44.838B | 0.30% | | |
| 89.50 | 44.838B | 0.30% | | |
| 133.59 | 20.562B | 0.10% | | |
| 96.00 | 14.606B | 0.80% | | |
| 95.65 | 14.606B | 0.80% | |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Agilent Technologies, Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
RatingPrice TargetAnalyst Report: Veeva Systems Inc.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
RatingPrice TargetAnalyst Report: Grifols, S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
RatingPrice TargetAnalyst Report: The Cooper Companies, Inc.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
RatingPrice Target




















